Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Blocklisting Six Monthly Return

29th Dec 2014 07:00

RNS Number : 8020A
Hutchison China Meditech Limited
29 December 2014
 



 

 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

Blocklisting Six Monthly Return

 

 

London: Monday, 29 December 2014: Chi-Med announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 

Hutchison China MediTech Limited

2.

Name of scheme:

 

Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:

 

From 29 June 2014 to 28 December 2014

 

4.

Balance under scheme from previous return:

 

876,279 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 

Nil

6.

Number of securities issued/allotted under scheme during period:

180,228 ordinary shares of US$1 each

7.

Balance under scheme not yet issued/allotted at end of the period:

 

696,051 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 

2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:

53,076,676 ordinary shares of US$1 each

Name of contact:

 

Christian Hogg

Address of contact:

 

21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 

+852 2121 8200

 

 

Ends

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Panmure Gordon (UK) Limited

Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

 

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

 

About Chi-Med

 

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRUKUNRSUAUURA

Related Shares:

Hutchmed
FTSE 100 Latest
Value8,474.74
Change-133.74